Follow us on
Search News Archives
Conferences | Events
Lab Bulletin Media Partners
Novozymes Biopharma US Inc

Novozymes Biopharma US Inc

Novozymes Biopharma US Inc

Products

Contact Novozymes Biopharma US Inc


If you have not logged into the website then please enter your details below.

All articles from Novozymes Biopharma US Inc

  Novozymes expands collaboration with Upperton Limited to offer customers new albumin conjugation solution Novozymes BiopharmaNovozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has expanded its partnership with Nottingham-based research and development company, Upperton Limited, to offer customers a new albumin conjugation solution. By linking drugs to Novozymes' new Recombumin Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result...

 

  Novozymes Biopharma collaborates with the University of Oslo to develop enhanced albumin fusion technology that tailors the half-life of proteins Albufuse Flex Novozymes Biopharma, part of Novozymes A/S, the world leader in bioinnovation, has unveiled its enhanced next-generation albumin technology, which was developed in collaboration with the University of Oslo, Norway, one of the world's leading institutions in the research of albumin variants and the neonatal Fc receptor (FcRn). Built on Novozymes' original Albufuse platform, the proprietary Albufuse Flex technology has been designed to enable users to adapt and control the pharmacokinetics of their target protein or peptide with retained efficacy, ensuring flexibility and optimal use...

 

  Novozymes Biopharma Presents Research on Recombinant Human Albumin at 2011 PepTalk Conference Novozymes BiopharmaNovozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, is presenting two scientific posters on the manufacturing and use of recombinant albumin in formulation during PepTalk 2011, 10-14 January, San Diego, US. The posters cover the company's latest research in the use of recombinant human albumin and its ability to address many of the formulation challenges faced by the industry

 

  Novozymes spotlights innovative solutions for medical devices, drug delivery and formulation at CPhI 2010 Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will be highlighting its innovative sodium hyaluronate and recombinant human albumin products at CPhI Wordwide 2010.

 

  Novozymes showcases leading biopharmaceutical solutions at BioProcess International 2010 Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will be showcasing its innovative portfolio of biopharmaceutical technologies and solutions at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition, 20-24 September at Rhode Island Convention Center, Providence, RI, USA.

 

  Novozymes announces master file for recombinant albumin Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, today announced that the US Food and Drug Administration Center for Biologics Evaluation and Research (FDA / CBER) has accepted a Type IV Master File for its recombinant albumin, albucult®.

 

  SAFC and Novozymes Biopharma extend joint agreement for the exclusive distribution of LONGR3 growth factor SAFC®, a member of the Sigma-Aldrich® Group (NASDAQ: SIAL), and Novozymes Biopharma DK A/S today announced a 10-year extension of their joint agreement under which SAFC retains exclusive marketing and distribution rights for Novozymes Biopharma's LONG®RÂłIGF-I (LONG®R3) growth factor used for industrial cell culture applications.